Viagra vs Cialis: Which ED Pill Is Right for You?

How Sildenafil and Tadalafil Actually Work

Both drugs block phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in penile smooth muscle. When PDE5 is inhibited, cyclic GMP accumulates, smooth muscle relaxes, and arterial blood flow into the corpus cavernosum increases during sexual stimulation. Neither drug produces an erection without arousal. That single mechanistic fact is often missed in online comparisons.

The two molecules are structurally distinct, which explains their different pharmacokinetic profiles. Sildenafil has a plasma half-life of roughly 3 to 5 hours. Tadalafil's half-life is 17.5 hours, nearly four times longer, which is why a single 20 mg dose can produce clinically meaningful effects through the following morning. The FDA prescribing information for tadalafil documents this half-life difference explicitly.

Cyclic GMP is also present in vascular smooth muscle throughout the body. PDE5 inhibitors therefore carry a blood-pressure-lowering effect even outside the penis. That effect becomes dangerous when organic nitrates are co-administered, because nitrates generate nitric oxide that independently raises cyclic GMP. The combination can cause severe, potentially fatal hypotension. The FDA label for both drugs lists nitrates as an absolute contraindication.

Onset and Duration: The Practical Difference

Sildenafil's 30 to 60 minute onset requires planning. Eat a high-fat meal beforehand and absorption slows further, with peak plasma concentration delayed by up to 60 minutes and maximum concentration reduced by 29%. That meal effect is real and clinically significant. Tadalafil, by contrast, shows no meaningful food interaction at any approved dose, which is why many men find it more forgiving in real-world use.

A randomized crossover study published in the International Journal of Impotence Research (N=150) found that men assigned to tadalafil 20 mg reported significantly higher satisfaction scores on the International Index of Erectile Function (IIEF) at 36 hours post-dose compared to sildenafil 100 mg, where efficacy had largely dissipated. See the IIEF validation data at PubMed. At the 2-hour window, the two drugs performed comparably.

For men who want maximum spontaneity, tadalafil wins on duration. For men who prefer a predictable 4 to 6 hour window and a clear "off" period, sildenafil may feel more controlled. Neither answer is wrong.

Dosing Options Side by Side

Sildenafil (Viagra and generic)

The standard starting dose is 50 mg taken 30 to 60 minutes before sexual activity. Prescribers may adjust to 25 mg if the patient is over 65, has hepatic impairment, or is on CYP3A4 inhibitors like ketoconazole. The maximum dose is 100 mg. The drug should not be taken more than once in 24 hours.

Tadalafil (Cialis and generic)

Two distinct prescribing strategies exist:

On-demand dosing. Tadalafil 10 mg or 20 mg, taken at least 30 minutes before anticipated activity, with effects possible for up to 36 hours. Maximum frequency is once per 24 hours.

Daily dosing. Tadalafil 2.5 mg or 5 mg taken once daily at the same time each day, regardless of sexual activity. Steady-state plasma levels are reached within 5 days. This approach eliminates the need to time dosing relative to sex. The FDA approved the 5 mg daily indication for both ED and BPH in 2011.

No equivalent FDA-approved daily sildenafil regimen for ED exists. Prescribers occasionally use off-label low-dose sildenafil daily in specific populations, but the evidence base for that strategy is thinner than for daily tadalafil.

Cialis Daily vs Cialis On Demand

The choice between daily and on-demand tadalafil comes down to frequency of sexual activity and lifestyle preference. A 2006 randomized trial (N=268) published in Urology compared daily tadalafil 5 mg against on-demand tadalafil 20 mg and found that IIEF-EF domain scores improved by 7.0 points in the daily group versus 6.7 points in the on-demand group, a difference that was not statistically significant at P = 0.67. View the study on PubMed.

Cost is a real factor. Daily 5 mg tadalafil in generic form typically runs $1, 2 per day at compounding or major pharmacies, making it genuinely affordable for consistent users. On-demand 20 mg tablets are more expensive per unit but cheaper if sex occurs fewer than 3 times per week.

Men with BPH have a specific reason to prefer daily 5 mg tadalafil. A meta-analysis in European Urology (2009, N=1,053 pooled) found that tadalafil 5 mg daily reduced International Prostate Symptom Score (IPSS) by a mean of 3.8 points versus 1.7 points for placebo (P<0.001). See the European Urology publication. Sildenafil has no approved BPH indication.

Side Effect Profiles Compared

Both drugs share a class-effect side effect profile rooted in their PDE5 inhibition and modest systemic vasodilation. Common reactions include headache (10 to 16% of patients), facial flushing (10 to 12%), and dyspepsia (4 to 7%). The FDA's MedWatch database documents reported adverse events for both agents.

Two side effects differ between the molecules:

Visual disturbances. Sildenafil inhibits PDE6, an enzyme in retinal photoreceptors that shares structural similarity with PDE5. Approximately 3 to 11% of men on sildenafil report transient blue-tinted vision or increased light sensitivity, especially at the 100 mg dose. Tadalafil has much lower PDE6 affinity and produces visual symptoms in fewer than 1% of patients.

Back pain and myalgia. Tadalafil inhibits PDE11, found in skeletal muscle and testicular tissue. About 3 to 6% of men on tadalafil report lower back pain or muscle aches, typically appearing 12 to 24 hours after dosing and resolving within 48 hours. Sildenafil rarely causes this symptom.

Nasal congestion affects both drugs at similar rates (4 to 5%). The risk of priapism (erection lasting more than 4 hours) is below 0.1% for both agents in clinical trial populations, though it rises with certain medications including antipsychotics and alpha-blockers.

Sildenafil vs Vardenafil: The Overlooked Comparison

Vardenafil (formerly marketed as Levitra, now available only as generic since brand discontinuation) is often overshadowed in the Viagra-vs-Cialis debate. The pharmacodynamics are nearly identical to sildenafil: 30 to 60 minute onset, 4 to 6 hour duration, strong PDE6 inhibition with similar visual side effect potential.

The one area where vardenafil may offer a clinical advantage is selectivity. Vardenafil's IC50 for PDE5 is approximately 0.7 nM, compared to 3.5 nM for sildenafil, meaning vardenafil binds PDE5 roughly five times more potently in vitro. A selectivity comparison is summarized in this NIH pharmacology review. Whether that translates to clinically meaningful superiority in men with severe ED or diabetes has not been conclusively demonstrated in head-to-head trials.

Vardenafil is available in a 10 mg orally disintegrating tablet (Staxyn formulation) that dissolves under the tongue without water. Some men find this convenient. The orodispersible form has slightly faster absorption than the standard tablet, with Tmax around 60 minutes versus 90 minutes for the film-coated version.

For most men, sildenafil and vardenafil are clinically interchangeable, and generic sildenafil is considerably cheaper. Vardenafil may be worth trying if a man has had unsatisfactory results with sildenafil or finds the visual side effects bothersome.

Avanafil (Stendra): The Fast-Onset Option

Avanafil deserves a brief mention because its pharmacokinetic profile is distinct from the three older agents. At the 200 mg dose, avanafil can produce response within 15 minutes in some men, a faster onset than any other oral PDE5 inhibitor. The key Phase 3 trial (N=646) in the Journal of Sexual Medicine showed that 64% of avanafil patients achieved successful intercourse versus 27% placebo at 15 minutes post-dose.

Avanafil has high PDE5 selectivity and does not meaningfully inhibit PDE6 or PDE11, which theoretically reduces both visual disturbances and back pain. The main downside is cost: generic avanafil is not widely available, and brand Stendra carries a higher out-of-pocket price than generic sildenafil or tadalafil.

PDE5 Inhibitor vs Trimix: When Pills Are Not Enough

Trimix is an intracavernosal injection containing three vasoactive agents: alprostadil (a prostaglandin E1 analog), papaverine (a non-selective PDE inhibitor), and phentolamine (an alpha-adrenergic blocker). It works through a fundamentally different mechanism than PDE5 inhibitors, directly relaxing cavernosal smooth muscle without requiring either PDE5 inhibition or sexual arousal. Erection typically begins within 5 to 10 minutes of injection and lasts 30 to 60 minutes, adjustable by dose.

Trimix is generally reserved for men who have failed PDE5 inhibitor therapy. Failure rates with PDE5 inhibitors run higher in men post-radical prostatectomy, men with severe vascular disease, and men with insulin-dependent diabetes and significant neuropathy. A 2016 systematic review in Journal of Sexual Medicine (N=3,458 pooled from 25 studies) found that intracavernosal alprostadil-based regimens produced successful erection in approximately 80% of men who had not responded to oral PDE5 inhibitors. Access the systematic review on PubMed.

Trimix requires self-injection technique, refrigerated storage, and carries a 1 to 5% rate of priapism that mandates clear patient education. A urologist or trained telehealth prescriber should supervise dose titration. PDE5 inhibitors remain first-line because of their non-invasive administration and established safety profile in primary care settings. Trimix is an effective second-line or rescue option, not a direct competitor for the typical ED patient.

PT-141 vs PDE5 Inhibitors: A Different Pathway Entirely

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist approved by the FDA in June 2019 under the brand name Vyleesi, specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. Its mechanism has nothing to do with blood flow. Bremelanotide activates MC3R and MC4R receptors in the hypothalamus, modulating central dopaminergic and serotonergic circuits involved in sexual motivation and desire.

Off-label use in men is investigational. Small pilot studies suggest that bremelanotide may increase sexual desire and produce partial erectile response in some men with psychogenic ED or men who have not responded to PDE5 inhibitors. A Phase 2 dose-escalation trial published in the Journal of Urology (N=324 men) found that 60 to 75% of bremelanotide-treated men reported improved erections versus 29% placebo, though the compound had not yet reached its current subcutaneous formulation at the time. The current approved formulation (1.75 mg subcutaneous auto-injector) is studied only in women.

The key distinction: PDE5 inhibitors address the vascular mechanics of erection. PT-141 targets central desire circuitry. They are theoretically complementary rather than interchangeable. A man with intact desire but poor vascular function needs a PDE5 inhibitor. A man with adequate vascular function but low sexual motivation may derive more benefit from bremelanotide combined with an evaluation of testosterone and psychological factors.

Nausea (40% of subjects), flushing, and transient blood pressure increases are the primary side effects of bremelanotide. These are substantially more common than the side effects of oral PDE5 inhibitors, which limits its practical appeal for routine off-label male use.

How to Choose: A Clinical Decision Framework

The following criteria map clinical situations to first-choice agents, based on the pharmacology reviewed above.

Choose sildenafil (generic Viagra) if:

• You want the lowest out-of-pocket cost (as low as $0.50 per dose at major pharmacy chains with GoodRx).
• Sex is planned and you can take the pill on an empty stomach 45 minutes before.
• You prefer a defined, time-limited window of effect.
• You are already familiar with the medication and tolerating it well.

Choose on-demand tadalafil (generic Cialis) if:

• Spontaneity matters and you dislike planning around meals.
• You are comfortable with a longer duration and want a "forgiving" pharmacokinetic window.
• You have tried sildenafil and found the visual side effects bothersome.

Choose daily tadalafil 5 mg if:

• You have sex three or more times per week and do not want to time dosing at all.
• You also have lower urinary tract symptoms (LUTS) or BPH.
• Psychological performance anxiety around "taking the pill" is a barrier for you.

Consider vardenafil if:

• Sildenafil has failed at maximum dose and you have not yet tried a chemical variant.
• You want the orodispersible convenience tablet format.

Escalate to trimix or refer to urology if:

• Two separate PDE5 inhibitors at maximum recommended dose have failed after at least six properly timed attempts.
• You have had radical prostatectomy with bilateral nerve sacrifice.
• Severe penile vascular insufficiency has been confirmed on duplex Doppler ultrasound.

Discuss PT-141 with your prescriber if:

• Desire and arousal are the primary concerns, not erectile mechanics.
• You have low testosterone ruled out or treated and still have psychogenic barriers to desire.

Drug Interactions and Contraindications

Organic nitrates are the single most important contraindication for every PDE5 inhibitor without exception. This includes nitroglycerin (all forms), isosorbide mononitrate, isosorbide dinitrate, and amyl nitrite ("poppers"). The FDA label states that concurrent use is absolutely contraindicated. Men presenting to emergency departments with chest pain who have taken a PDE5 inhibitor within the previous 24 to 48 hours must inform the treating physician, because nitroglycerin administration could precipitate severe hypotension.

Alpha-blockers (tamsulosin, doxazosin, terazosin) used for BPH can produce additive hypotension with PDE5 inhibitors. The interaction is particularly relevant for men on daily tadalafil 5 mg who are also taking tamsulosin. The FDA labeling for tadalafil addresses the alpha-blocker interaction in detail. Starting with the lowest PDE5 inhibitor dose and timing doses to be separated from alpha-blocker administration by at least 4 hours reduces the risk.

Strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole) raise plasma concentrations of all PDE5 inhibitors substantially. With ritonavir co-administration, sildenafil's maximum recommended dose drops to 25 mg per 48 hours. Grapefruit juice is a mild CYP3A4 inhibitor and may modestly extend drug action.

What the Evidence Says About Efficacy

The landmark STEP-1 equivalent in the ED space was the original pre-approval sildenafil trial program. A pooled analysis of 11 double-blind, placebo-controlled trials (N=1,654 men with ED of various etiologies) found that sildenafil produced erections sufficient for intercourse in 70% of attempts versus 26% for placebo. Access the original Goldstein et al. 1998 NEJM trial reporting sildenafil approval data.

For tadalafil, the key Phase 3 program (Porst et al., European Urology, 2002, N=179) showed that tadalafil 20 mg produced successful intercourse in 75% of attempts versus 32% placebo. See the European Urology publication via PubMed.

Direct head-to-head comparisons are less common and methodologically varied. A 2013 Cochrane systematic review (Tsertsvadze et al., 14 trials, N=1,756) found no statistically significant difference in IIEF-EF scores between sildenafil and tadalafil across the pooled analysis. The Cochrane review is accessible here. As the review concluded: "no single drug demonstrated superior efficacy over another; the choice should be based on individual patient preference and lifestyle considerations."

Men with diabetes represent a population where all PDE5 inhibitors show modestly lower response rates. A dedicated tadalafil trial in diabetic men (N=216, Saenz de Tejada et al., 2002) showed tadalafil 20 mg improved IIEF-EF domain scores by 6.4 points versus 1.1 placebo (P<0.001). Access that trial on PubMed.

Getting a Prescription

Both drugs require a prescription in the United States. Telehealth platforms including HealthRX can issue a prescription after a synchronous or asynchronous clinical evaluation. Expect the prescriber to ask about cardiovascular history, nitrate use, blood pressure, current medications, and prior ED treatment history. Men with uncontrolled hypertension, recent myocardial infarction within 90 days, or stroke within 6 months are typically not candidates for elective PDE5 inhibitor therapy until cardiovascular status is stabilized.

Generic sildenafil 20 mg tablets (originally approved for pulmonary arterial hypertension) are sometimes prescribed at a dose of 3x20 mg = 60 mg or 5x20 mg = 100 mg to take advantage of the lower insurance tier or cash price. This is a common and clinically accepted off-label dosing approach. The 20 mg tablet became generic in 2017; the FDA-labeled 25/50/100 mg ED tablets followed. FDA approval history is documented in the FDA Orange Book.

Men who have failed two PDE5 inhibitors at maximum dose after six properly timed attempts with adequate sexual stimulation should be referred for in-person urological evaluation, including penile Doppler ultrasound to assess arterial inflow.